ASCO 2022: A Trio of Promising Treatments for Bladder Cancer

Tracy L. Rose, MD, MPH


June 14, 2022

Tracy Rose, MD, enthusiastically discusses three presentations on recent bladder cancer research at ASCO 2022. The first, on the QUILT 3.032 trial, offered results with the combined therapeutic agents bacille Calmette-Guérin (BCG) and the interleukin-15 superagonist N-803 for treatment in patients with BCG-unresponsive, non–muscle-invasive cancer. In the muscle-invasive realm, Dr Rose reviews the data presented regarding the phase 2 SAKK 06/17 trial, which brought the monoclonal antibody durvalumab together with chemotherapy and rendered intriguing preliminary results.

Finally, Dr Rose describes a poster discussion in which a combination of antibody-drug conjugate and immunotherapy was presented — an investigation that produced an impressive overall response rate in the treatment of metastatic urothelial cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.